Takara Bio Stock

Takara Bio FCF Conversion

Delisted·Jun 12, 2026

The FCF Conversion Rate (FCF/EBITDA) of Takara Bio (4974.T) as of Aug 11, 2026 is -425.53 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -754.05 % — a change of -43.57% (higher).

FCF Conversion

-425.53 %

YoY

-43.57%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Takara Bio is 2026 -425.53 % . FCF Conversion Rate (FCF/EBITDA) of Takara Bio was 2025 -754.05 % . It decreases by -43.57% higher compared to the previous year.
Access this data via the Eulerpool API

Takara Bio Stock analysis

What does Takara Bio do? Takara Bio Inc is a Japanese biotechnology company that has been active in the medical and life science industry since its founding in 1967. The company is a strong player in the field of molecular biology and operates in several countries such as the USA, Europe, and Asia. Takara Bio Inc was established as an independent company in 1999, focusing exclusively on the production of molecular biology products. The company offers a wide range of products in the fields of research and diagnostics, including enzymes, PCR kits, vectors and plasmids, antibodies, proteins, and cell culture products. Takara Bio Inc is organized into two divisions: Life Science Research and Diagnostics. The Life Science Research division provides products and solutions for research and development in areas such as molecular biology, neuroscience, proteomics, and genomics. The Diagnostics division offers products and solutions for clinical diagnostics and drug development. Takara Bio Inc also specializes in the automation of molecular biology procedures and offers automated systems that can perform processes such as nucleic acid extraction, PCR, and sequencing. The company is committed to sustainability and environmental protection, adhering to strict environmental and quality standards in its production processes and implementing waste reduction and efficient resource utilization programs. Overall, Takara Bio Inc is a leading company in the field of molecular biology, offering a wide range of products and solutions for research and diagnostics, and has become a key player in the life science industry through its global expansion and ability to provide custom solutions. Takara Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Takara Bio stock

FCF Conversion Rate (FCF/EBITDA) of Takara Bio is -425.53 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Takara Bio changed from -754.05 % to -425.53 %, representing a -43.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Takara Bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Takara Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Takara Bio

All Key Metrics — Takara Bio